Side Effects Of Drugs Used In Cancer Chemotherapy

Pylak-Piwko, Oktawia; Nieradko-Iwanicka, Barbara

doi:10.5281/zenodo.1054556

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Premature release is undesirable in controlled delivery systems because high-level release of anticancer drugs can damage healthy tissue and lead to serious adverse effects . Some examples of adverse effects mainly include physical weakness, myelosuppression, heart and liver toxicity, digestive disorders, decreased immune function, and neurotoxicity. , For this reason, the ideal PLGA NPs need to avoid premature release in the bloodstream and should support triggered release in tumor tissue thereafter. To address this challenge, Chen et al have demonstrated that chitosan-coated PLGA NPs can decrease premature release and display pH-responsive drug release compared with those of uncoated NPs .…”

Section: Introductionmentioning

confidence: 99%

PEGylated-PLGA Nanoparticles Coated with pH-Responsive Tannic Acid–Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer

Zhang

Guo

et al. 2020

Mol. Pharmaceutics

View full text Add to dashboard Cite

Biodegradable poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) have been widely used as delivery vehicles for chemotherapy drugs. However, premature drug release in PLGA NPs can damage healthy tissue and cause serious adverse effects during systemic administration. Here, we report a tannic acid− Fe(III) (Fe III −TA) complex-modified PLGA nanoparticle platform (DOX-TPLGA NPs) for the tumor-targeted delivery of doxorubicin (DOX). A PEGylated-PLGA inner core and Fe III −TA complex outer shell were simultaneously introduced to reduce premature drug release in blood circulation and increase pH-triggered drug release in tumor tissue. Compared to the unmodified NPs, the initial burst rate of DOX-TPLGA NPs was significantly reduced by nearly 2-fold at pH 7.4. Moreover, the cumulative drug release rate at pH 5.0 was 40% greater than that at pH 7.4 due to the pH-response of the Fe III −TA complex. Cellular studies revealed that the TPLGA NPs had enhanced drug uptake and superior cytotoxicity of breast cancer cells in comparison to free DOX. Additionally, the DOX-TPLGA NPs efficiently accumulated in the tumor site of 4T1-bearing nude mice due to the enhanced permeability and retention (EPR) effect and reached a tumor inhibition rate of 85.53 ± 8.77% (1.31-fold versus DOX-PLGA NPs and 3.12-fold versus free DOX). Consequently, the novel TPLGA NPs represent a promising delivery platform to enhance the safety and efficacy of chemotherapy drugs.

show abstract